{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Anti-diabetes+Drugs+alone", "query": { "intervention": "Oral Anti-diabetes Drugs alone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T16:19:30.891Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04416269", "title": "Oral Anti Diabetic Agents in the Hospital", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Oral Anti-diabetes Drugs alone", "type": "DRUG" }, { "name": "Basal bolus insulin", "type": "DRUG" }, { "name": "Supplemental insulin", "type": "DRUG" }, { "name": "Continuous glucose monitoring (CGM)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 85, "start_date": "2020-08-07", "completion_date": "2025-04-11", "has_results": true, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416269" }, { "nct_id": "NCT03169959", "title": "A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "2.5 mg Saxagliptin tablet", "type": "DRUG" }, { "name": "5 mg dapagliflozin / 1000 mg metformin XR tablet", "type": "DRUG" }, { "name": "Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR", "type": "DRUG" }, { "name": "5 mg saxagliptin", "type": "DRUG" }, { "name": "10 mg dapagliflozin / 1000 mg metformin XR tablet", "type": "DRUG" }, { "name": "Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 85, "start_date": "2017-05-29", "completion_date": "2017-08-03", "has_results": false, "last_update_posted_date": "2017-08-14", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03169959" }, { "nct_id": "NCT01336023", "title": "Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/liraglutide", "type": "DRUG" }, { "name": "insulin degludec", "type": "DRUG" }, { "name": "liraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1663, "start_date": "2011-05-23", "completion_date": "2012-11-22", "has_results": true, "last_update_posted_date": "2018-02-19", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 146, "location_summary": "Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bermuda Dunes", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01336023" }, { "nct_id": "NCT02787551", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/lixisenatide fixed ratio combination", "type": "DRUG" }, { "name": "liraglutide", "type": "DRUG" }, { "name": "exenatide", "type": "DRUG" }, { "name": "exenatide extended-release", "type": "DRUG" }, { "name": "albiglutide", "type": "DRUG" }, { "name": "dulaglutide", "type": "DRUG" }, { "name": "Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 514, "start_date": "2016-07-06", "completion_date": "2018-11-17", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02787551" }, { "nct_id": "NCT06830096", "title": "Role of KATP Channel Loss in Type 2 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity and Type 2 Diabetes" ], "interventions": [ { "name": "10 mg glipizide ingestion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2025-03-07", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06830096" }, { "nct_id": "NCT04531176", "title": "EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes", "Obesity" ], "interventions": [ { "name": "Weight Management Program (WMP)", "type": "OTHER" }, { "name": "Traditional care", "type": "OTHER" }, { "name": "Phentermine / Topiramate Extended Release Oral Capsule", "type": "DRUG" }, { "name": "naltrexone/bupropion extended-release", "type": "DRUG" }, { "name": "liraglutide 3.0 mg", "type": "DRUG" }, { "name": "Orlistat", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 74, "start_date": "2020-09-01", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04531176" }, { "nct_id": "NCT07754461", "title": "A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Survodutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2026-08-24", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 81 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07754461" }, { "nct_id": "NCT00332488", "title": "Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Technosphere Insulin", "type": "DRUG" }, { "name": "Metformin & Secretagogues", "type": "DRUG" }, { "name": "Technosphere Insulin & Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 547, "start_date": "2004-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-10-16", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00332488" }, { "nct_id": "NCT01128621", "title": "A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "GSK1292263", "type": "DRUG" }, { "name": "GSK1292263 matching placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 66, "start_date": "2009-11-23", "completion_date": "2010-04-12", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 2, "location_summary": "Chula Vista, California • Miami, Florida", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01128621" }, { "nct_id": "NCT01068860", "title": "To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus", "Impaired Glucose Tolerance" ], "interventions": [ { "name": "Canakinumab 150 mg", "type": "DRUG" }, { "name": "Placebo to Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 246, "start_date": "2010-02", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-09-05", "last_synced_at": "2026-10-04T16:19:30.891Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068860" } ] }